HLA class I subtypes are associated with immune-related adverse events in patients with melanoma treated with ipilimumab Meeting Abstract
| Authors: | Safonov, A.; Pluta, J.; Qian, L.; Amaravadi, R.; Applegate, A.; Buchbinder, E.; Cohen, J.; Friedman, C.; Halaban, R.; Hodi, F. S.; Horak, C.; Johnson, D.; Kirkwood, J.; Mitchell, T.; Robinson, W.; Schuchter, L.; Sosman, J.; Sznol, M.; Wind-Rotolo, M.; Wolchok, J.; Li, M.; Kanetsky, P.; Nathanson, K. L. |
| Abstract Title: | HLA class I subtypes are associated with immune-related adverse events in patients with melanoma treated with ipilimumab |
| Meeting Title: | 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 6 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Nov 7-11 |
| Meeting Location: | Washington, DC |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2018-11-06 |
| Start Page: | 114 |
| Language: | English |
| PMCID: | PMC6220480 |
| PUBMED: | 30400835 |
| DOI: | 10.1186/s40425-018-0422-y |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: P108 |
Altmetric
Citation Impact
BMJ Impact Analytics
